CompletedNot applicableNCT03926845

Efficacy and Tolerability of an Isobutylamido-thiazolyl-resorcinol Cream 0.2% for Facial Hyperpigmentation

Studying Disorder of melanin metabolism

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institute of Dermatology, Thailand
Principal Investigator
Chinmanat Lekhavat, MD
Institute of Dermatology
Intervention
Isobutylamido-thiazolyl-resorcinol Cream 0.2%(other)
Enrollment
200 target
Eligibility
18 years · All sexes
Timeline
20192021

Study locations (1)

Collaborators

Beiersdorf (Thailand) Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03926845 on ClinicalTrials.gov

Other trials for Disorder of melanin metabolism

Additional recruiting or active studies for the same condition.

See all trials for Disorder of melanin metabolism

← Back to all trials